A research group at the University of Tokyo has created an oral cholera vaccine encased in rice protein that could be used in large-scale cost effective vaccination programs, according to a report by Reuters. The vaccine, which proved effective in protecting mice from the disease, does not require refrigeration and is provided as a capsule.
The group said that, because rice protein is stable in acidic environments, the vaccine is able to transit through the stomach to the small intestine where it triggers an immune response to cholera antigen. The researchers plan to begin primate trials in the future, with the eventual aim of initiating human clinical evaluation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze